跳至主要内容
临床试验/ISRCTN14366792
ISRCTN14366792终止未知

Impact of telemedicine activation of older patients with polypharmacy: a randomised acceptance and feasibility study in Switzerland

niversity of Zurich0 个研究点目标入组 0 人开始时间: 2019年3月29日最近更新:

试验速览

阶段
未知
状态
终止
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Patients insured at SWICA
  • 2. German-speaking
  • 3. 60 years or older
  • 4. Using at least five different drugs, at least three original packages over the last 12 months and at least one month distance in between. Exception of this 12 months rule and included in the data are androgens, vitamin B12, antineoplastic and immunemodulating agents and drugs for treating osteoporosis. Excluded drugs are topical (including dermatologicals, nasal-, throat-, cough and cold preparations, transdermal opioids), intravenous and homeopathic drugs, vaccines, surgical dressings, contrast agents as well as products from these pharmaceutical companies (Ceres®, Similisan®, Omnida®, Spagyros® and Vogel®)
  • 5. Signed Informed Consent after being informed

排除标准

  • Patients insured at SWICA with a GP guided healthcare plan

研究者

发起方
niversity of Zurich

相似试验